Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMQ08AJ)

• Drug Name: Edotreotide Drug Info
• Synonyms: Edotreotide; SMT-487; UNII-U194AS08HZ; 204318-14-9; U194AS08HZ; CHEMBL408350; DOTATOC; DOTA-D-PHE-CYS-TYR-D-TRP-LYS-THR-CYS-THR-OL (DISULFIDE BRIDGE: 2-7); SMT 487; Edotreotide [USAN:INN]; DOTA-TOC acetate; AC1L4KLV; SCHEMBL1649285; SCHEMBL19712197; RZHKDBRREKOZEW-AAXZNHDCSA-N; BDBM50165171; N-((4,7,10-Tris(carboxymethyl)-1,4,7,10-tetraazacycoldodec-1-yl)acetyl-D-phenylalanyl-L-cysteinyl-L-tyrosyl-D-tryprophyl-L-lysyl-L-threonyl-N-((1R,2R)-2-hydroxy-1-(hydroxymethyl)propyl)-L-cysteinamide cyclic (2-7)-disulfide

Indication

Disease Entry	ICD 11	Status	REF
Acromegaly	5A60.0	Phase 2	[1]

• Cross-matching ID:
  PubChem CID: 158782
  CAS Number: CAS 204318-14-9
  TTD Drug ID: DMQ08AJ

Molecule-Related Drug Atlas

Drug(s) Targeting Somatostatin receptor (SSTR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
177Lu-DOTA-octreotate	DMP5L8S	Melanoma	2C30	Phase 3	[4]
177-Lu-oxodotreotide	DMMZS2T	Neuroendocrine cancer	2B72.1	Phase 3	[5]
177Lu-DOTATATE	DMT8GVU	Hepatitis C virus infection	1E51.1	Phase 2	[4]
Somatoprim	DMTVS3A	Acromegaly	5A60.0	Phase 2	[6]
FK-962	DMV0MZ3	Alzheimer disease	8A20	Phase 2	[7]
177Lu-labelled DOTA-JR11	DMVZ9XL	Neuroendocrine cancer	2B72.1	Phase 1/2	[8]
212Pb-labelled DOTAMTATE	DMN9MPX	Neuroendocrine cancer	2B72.1	Phase 1	[9]
AlphaMedix	DMBVM1Q	Neuroendocrine cancer	2B72.1	Phase 1	[10]
FK-960	DMPD8O2	Cognitive impairment	6D71	Discontinued in Phase 2	[7]
SEGLITIDE	DMXZVPH	Pain	MG30-MG3Z	Discontinued in Phase 2	[11]

Drug(s) Affected By Somatostatin receptor type 2 (SSTR2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Pasireotide	DMHM7JS	Cushing disease	5A70	Approved	[12]
Tretinoin	DM49DUI	Acne vulgaris	ED80	Approved	[13]
Arsenic trioxide	DM61TA4	Acute lymphoblastic leukaemia	2A85	Approved	[14]
Valproate	DMCFE9I	Epilepsy	8A60-8A68	Approved	[15]
Malathion	DMXZ84M	Pediculus capitis infestation	1G00.0	Approved	[16]
Permethrin	DMZ0Q1G	Pediculus capitis infestation	1G00.0	Approved	[16]
SNDX-275	DMH7W9X	Breast cancer	2C60-2C65	Phase 3	[17]
Benzo(a)pyrene	DMN7J43	N. A.	N. A.	Phase 1	[18]
PMID26394986-Compound-22	DM43Z1G	N. A.	N. A.	Patented	[19]
Formaldehyde	DM7Q6M0	Discovery agent	N.A.	Investigative	[20]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Somatostatin receptor (SSTR)	TTOMNR9	NOUNIPROTAC	Modulator	[2]

Drug Off-Target (DOT)

DOT Name	DOT ID	UniProt ID	Interaction	REF
Somatostatin receptor type 2 (SSTR2)	OTFN8JM1	SSR2_HUMAN	Protein Interaction/Cellular Processes	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 5638).
• [2] Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
• [3] Locoregional regulatory peptide receptor targeting with the diffusible somatostatin analogue 90Y-labeled DOTA0-D-Phe1-Tyr3-octreotide (DOTATOC): a pilot study in human gliomas. Clin Cancer Res. 1999 May;5(5):1025-33.
• [4] Peptide receptor radionuclide therapy with 177Lu-DOTATATE for patients with somatostatin receptor-expressing neuroendocrine tumors: the first US phase 2 experience. Pancreas. 2014 May;43(4):518-25.
• [5] Lutetium-labelled peptides for therapy of neuroendocrine tumours. Eur J Nucl Med Mol Imaging. 2012 Feb;39 Suppl 1(Suppl 1):S103-12.
• [6] DG3173 (somatoprim), a unique somatostatin receptor subtypes 2-, 4- and 5-selective analogue, effectively reduces GH secretion in human GH-secreting pituitary adenomas even in Octreotide non-responsive tumours.Eur J Endocrinol.2012 Feb;166(2):223-34.
• [7] FK960, a novel potential anti-dementia drug, enhances high K(+)-evoked release of somatostatin from rat hippocampal slices. Brain Res. 2001 Feb 16;892(1):111-7.
• [8] Multimodal Imaging of 2-Cycle PRRT with 177 Lu-DOTA-JR11 and 177 Lu-DOTATOC in an Orthotopic Neuroendocrine Xenograft Tumor Mouse Model. J Nucl Med. 2021 Mar;62(3):393-398.
• [9] Radiopharmaceutical therapy in cancer: clinical advances and challenges. Nat Rev Drug Discov. 2020 Sep;19(9):589-608.
• [10] Clinical pipeline report, company report or official report of Orano Med.
• [11] Antagonist effects of seglitide (MK 678) at somatostatin receptors in guinea-pig isolated right atria.. Br J Pharmacol. 1993 August; 109(4): 898-899.
• [12] Medicinal chemistry of somatostatin analogs leading to the DTPA and DOTA conjugates of the multi-receptor-ligand SOM230. J Endocrinol Invest. 2005;28(11 Suppl International):15-20.
• [13] Development of a neural teratogenicity test based on human embryonic stem cells: response to retinoic acid exposure. Toxicol Sci. 2011 Dec;124(2):370-7.
• [14] Identification of transcriptome signatures and biomarkers specific for potential developmental toxicants inhibiting human neural crest cell migration. Arch Toxicol. 2016 Jan;90(1):159-80.
• [15] Effects of lithium and valproic acid on gene expression and phenotypic markers in an NT2 neurosphere model of neural development. PLoS One. 2013;8(3):e58822.
• [16] Exposure to Insecticides Modifies Gene Expression and DNA Methylation in Hematopoietic Tissues In Vitro. Int J Mol Sci. 2023 Mar 26;24(7):6259. doi: 10.3390/ijms24076259.
• [17] A transcriptome-based classifier to identify developmental toxicants by stem cell testing: design, validation and optimization for histone deacetylase inhibitors. Arch Toxicol. 2015 Sep;89(9):1599-618.
• [18] Air pollution and DNA methylation alterations in lung cancer: A systematic and comparative study. Oncotarget. 2017 Jan 3;8(1):1369-1391. doi: 10.18632/oncotarget.13622.
• [19] Preoperative growth inhibition of human gastric adenocarcinoma treated with a combination of celecoxib and octreotide. Acta Pharmacol Sin. 2007 Nov;28(11):1842-50. doi: 10.1111/j.1745-7254.2007.00652.x.
• [20] Characterization of formaldehyde's genotoxic mode of action by gene expression analysis in TK6 cells. Arch Toxicol. 2013 Nov;87(11):1999-2012.